BIOL — BIOLASE Income Statement
0.000.00%
Last trade - 00:00
- $4.18m
- $16.03m
- $48.46m
- 31
- 35
- 12
- 15
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.2 | 37.8 | 22.8 | 39.2 | 48.5 |
Cost of Revenue | |||||
Gross Profit | 16.9 | 14.3 | 6.17 | 16.5 | 15.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 67 | 53.4 | 41.3 | 52.6 | 73.8 |
Operating Profit | -20.9 | -15.6 | -18.5 | -13.4 | -25.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -21.5 | -17.9 | -16.7 | -16.1 | -28.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22.1 | -17.9 | -16.8 | -16.2 | -28.6 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -21.5 | -17.9 | -16.8 | -16.2 | -28.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21.5 | -17.9 | -34.2 | -16.7 | -28.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,474 | -1,924 | -1,399 | -312 | -416 |